首页> 外文期刊>The Journal of Pathology: Clinical Research >Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience
【24h】

Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience

机译:基于细胞角蛋白的结直肠癌肿瘤萌发评估:II期患者的分析和前瞻性诊断经验

获取原文
           

摘要

Abstract Tumour budding in colorectal cancer is an important prognostic factor. A recent consensus conference elaborated recommendations and key issues for future studies, among those the use of pan-cytokeratin stains, especially in stage II patients. We report the first prospective diagnostic experience using pan-cytokeratin for tumour budding assessment. Moreover, we evaluate tumour budding using pan-cytokeratin stains and disease-free survival (DFS) in stage II patients. To this end, tumour budding on pan-cytokeratin-stained sections was evaluated by counting the number of tumour buds in 10 high-power fields (0.238 mm 2 ), then categorizing counts as low/high-grade at a cut-off of 10 buds, in two cohorts. Cohort 1: prospective setting with 236 unselected primary resected colorectal cancers analysed by 17 pathologists during diagnostic routine. Cohort 2: retrospective cohort of 150 stage II patients with information on DFS. In prospective analysis of cohort 1, tumour budding counts correlated with advanced pT, lymph node metastasis, lymphovascular invasion, perineural invasion (all p < 0.0001), and distant metastasis ( p = 0.0128). In cohort 2, tumour budding was an independent predictor of worse DFS using counts [ p = 0.037, HR (95% CI): 1.007 (1.0?¢????1.014)] and the low-grade/high-grade scoring approach [ p = 0.02; HR (95% CI): 3.04 (1.2?¢????7.77), 90.7 versus 73%, respectively]. In conclusion, tumour budding assessed on pan-cytokeratin slides is feasible in a large pathology institute and leads to expected associations with clinicopathological features. Additionally, it is an independent predictor of poor prognosis in stage II patients and should be considered for risk stratification in future clinical studies.
机译:摘要大肠癌中的肿瘤萌发是重要的预后因素。最近的共识会议详细阐述了建议和未来研究的关键问题,其中包括泛细胞角蛋白染色的使用,特别是在II期患者中。我们报告了使用泛细胞角蛋白进行肿瘤萌芽评估的首个前瞻性诊断经验。此外,我们评估了泛细胞角蛋白染色和II期患者的无病生存期(DFS)的肿瘤萌芽。为此,通过对10个高倍视野(0.238 mm 2)中的肿瘤芽数进行计数,然后将其分类为低/高等级(截止值为10),来评估泛细胞角蛋白染色切片上的肿瘤出芽。芽,在两个队列中。队列1:前瞻性背景,由236名未选择的原发性切除结直肠癌,由17名病理学家在诊断常规中进行了分析。队列2:回顾性队列150例DFS相关信息的II期患者。在队列1的前瞻性分析中,肿瘤出芽计数与晚期pT,淋巴结转移,淋巴管浸润,神经周浸润(均p <0.0001)和远处转移(p = 0.0128)相关。在队列2中,使用计数[p = 0.037,HR(95%CI):1.007(1.0≤1.0≤1.014)]和低/高评分方法可以单独判断肿瘤的发芽率。 [p = 0.02; HR(95%CI):3.04(1.2%7.77),分别为90.7对73%]。总之,在大型病理研究所中,在全细胞角蛋白载玻片上评估肿瘤萌芽是可行的,并导致与临床病理特征的预期关联。此外,它是II期患者预后不良的独立预测因素,在以后的临床研究中应考虑风险分层。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号